Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,168,283
  • Shares Outstanding, K 68,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -165 M
  • EBITDA $ -165 M
  • 60-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.85

Options Overview Details

View History
  • Implied Volatility 97.99% (-20.24%)
  • Historical Volatility 251.91%
  • IV Percentile 6%
  • IV Rank 8.47%
  • IV High 773.50% on 04/04/25
  • IV Low 35.47% on 09/02/25
  • Expected Move (DTE 7) 2.59 (7.96%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,168
  • Volume Avg (30-Day) 5,231
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 39,093
  • Open Int (30-Day) 24,357
  • Expected Range 29.98 to 35.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 5
  • High Estimate -0.50
  • Low Estimate -0.55
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -3.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.82 +317.90%
on 11/14/25
33.50 -2.44%
on 12/11/25
+24.62 (+305.46%)
since 11/12/25
3-Month
6.65 +391.43%
on 10/20/25
33.50 -2.44%
on 12/11/25
+24.91 (+320.59%)
since 09/12/25
52-Week
2.86 +1,042.66%
on 04/07/25
33.50 -2.44%
on 12/11/25
+25.96 (+386.31%)
since 12/12/24

Most Recent Stories

More News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

OLMA : 33.06 (+4.69%)
RHHBY : 50.0700 (+0.10%)
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer Initiated OPERA-02 Phase 3 trial of palazestrant...

OLMA : 33.06 (+4.69%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.06 (+4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 36.70
2nd Resistance Point 35.10
1st Resistance Point 33.34
Last Price 33.06
1st Support Level 29.98
2nd Support Level 28.38
3rd Support Level 26.62

See More

52-Week High 33.50
Last Price 33.06
Fibonacci 61.8% 21.79
Fibonacci 50% 18.18
Fibonacci 38.2% 14.56
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar